Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Iovance Biotherapeutics, Inc is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Iovance Biotherapeutics employs 241 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$18.57|
|52-week range||$17.24 - $54.21|
|50-day moving average||$24.40|
|200-day moving average||$31.72|
|Wall St. target price||$40.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-30.14%|
|3 months (2021-04-30)||-40.94%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-32.09%|
|Return on equity TTM||-59.6%|
|Market capitalisation||$3.4 billion|
TTM: trailing 12 months
There are currently 17.9 million Iovance Biotherapeutics shares held short by investors – that's known as Iovance Biotherapeutics's "short interest". This figure is 0.7% up from 17.7 million last month.
There are a few different ways that this level of interest in shorting Iovance Biotherapeutics shares can be evaluated.
Iovance Biotherapeutics's "short interest ratio" (SIR) is the quantity of Iovance Biotherapeutics shares currently shorted divided by the average quantity of Iovance Biotherapeutics shares traded daily (recently around 2.2 million). Iovance Biotherapeutics's SIR currently stands at 8.3. In other words for every 100,000 Iovance Biotherapeutics shares traded daily on the market, roughly 8300 shares are currently held short.
However Iovance Biotherapeutics's short interest can also be evaluated against the total number of Iovance Biotherapeutics shares, or, against the total number of tradable Iovance Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Iovance Biotherapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Iovance Biotherapeutics shares in existence, roughly 120 shares are currently held short) or 0.1393% of the tradable shares (for every 100,000 tradable Iovance Biotherapeutics shares, roughly 139 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Iovance Biotherapeutics.
Find out more about how you can short Iovance Biotherapeutics stock.
We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.
Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.
Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $17.24 up to $54.2081. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.8863. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).
Iovance Biotherapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M. D.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.